These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33589773)

  • 21. Clinical development of CT-P6 in HER2 positive breast cancer.
    Fu C; Stebbing J; Esteva FJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
    [No Abstract]   [Full Text] [Related]  

  • 22. [Biosimilars in oncology. Focus on SB3 studies.].
    Del Re M; Del Mastro L
    Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
    Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
    Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous versus subcutaneous trastuzumab: an economic and patient perspective.
    Mitchell H; Morrissey D
    Br J Nurs; 2019 May; 28(10):S15-S20. PubMed ID: 31116603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management.
    Cuellar S
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China.
    Deng W; Hu J; Li M; Yang S; Xie Z; Chen J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1117-1126. PubMed ID: 35899310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
    Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
    PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Trastuzumab and its biosimilars].
    Sarosiek T; Morawski P
    Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.
    Duco MR; Murdock JL; Reeves DJ
    Ann Pharmacother; 2020 Mar; 54(3):254-261. PubMed ID: 31595774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
    Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
    Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.
    Cargnin S; Shin JI; Genazzani AA; Nottegar A; Terrazzino S
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):577-588. PubMed ID: 33005979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
    Cesarec A; Likić R
    Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
    Apsangikar P; Chaudhry S; Naik M; Deoghare S; Joseph J
    Indian J Cancer; 2017; 54(4):664-668. PubMed ID: 30082554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
    Ciruelos EM; Montaño A; Rodríguez CA; González-Flores E; Lluch A; Garrigós L; Quiroga V; Antón A; Malón D; Chacón JI; Velasco M; Gonzalez-Cortijo L; Jolis L; Echarri MJ; Muñoz M; Pascual T; Amigo Y; Casas M; Carrasco E; Casas A
    Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13253. PubMed ID: 32578279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
    Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.